Data as of Sep 12, 2026. Both funds on the fields they both publish, from the same sources.
INDA vs XBI: how they differ
INDA and XBI hold 0% of their weight in the same names, and XBI returned more over the year.
iShares MSCI India ETF and State Street(R) SPDR(R) S&P(R) Biotech ETF.
What they hold in common
By the books each fund has filed, INDA and XBI hold 0% of their money in the same securities at the same weight.
| Only in INDA | Only in XBI |
|---|---|
| RELIANCE INDUSTRIES LIMITED 6.23% | Apogee Therapeutics Inc 1.49% |
| HDFC BANK LIMITED 6.15% | Moderna Inc 1.41% |
| ICICI BANK LIMITED 4.68% | Twist Bioscience Corp 1.41% |
| BHARTI AIRTEL LIMITED 3.63% | Oruka Therapeutics Inc 1.38% |
| INFOSYS LIMITED 2.92% | Kymera Therapeutics Inc 1.36% |
| AXIS BANK LIMITED 2.23% | Viking Therapeutics Inc 1.31% |
| MAHINDRA AND MAHINDRA LIMITED 2.20% | Praxis Precision Medicines Inc 1.29% |
| LARSEN AND TOUBRO LIMITED 2.13% | Erasca Inc 1.27% |
Weight overlap is an ETFIQ calculation: for every security both funds hold, the smaller of the two weights, summed. Above 50%, holding both is close to holding one of them twice. Holdings dated Jun 30, 2026 and May 31, 2026.
| INDA iShares MSCI India ETF | XBI State Street(R) SPDR(R) S&P(R) Biotech ETF | |
|---|---|---|
| Where it sits | Core index fund | Core index fund |
| Issuer | iShares | State Street |
| What it is | MSCI India | SPDR S&P Biotech |
| Total return, 1 year | −8.8% | +64.0% |
| S&P 500 over the same days | +17.5% | +17.5% |
| Gap to the S&P 500 | −26.3 pts | +46.5 pts |
| Expense ratio | 0.61% | 0.35% |
| Already in the S&P 500 | 0.0% | 8.5% |
| Holdings | 169 | 150 |
INDA in plain words
INDA is an index equity fund tracking the MSCI India. Over the year to Sep 11, 2026 it returned −8.8% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.61% a year. By its holdings filed for May 31, 2026, 0% of the fund by weight is stocks the S&P 500 also holds, across 169 positions, with the top ten at 33.7%. It sat 17.4% below its high of Sep 26, 2024 on Sep 11, 2026.
XBI in plain words
XBI is an index equity fund tracking the SPDR S&P Biotech. Over the year to Sep 11, 2026 it returned +64.0% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.35% a year. By its holdings filed for Jun 30, 2026, 8% of the fund by weight is stocks the S&P 500 also holds, across 150 positions, with the top ten at 13.3%. It sat 9.6% below its high of Feb 8, 2021 on Sep 11, 2026.
Questions people ask
- Which returned more over the last year, INDA or XBI?
- In the year to Sep 12, 2026, with distributions reinvested, INDA returned −8.8% and XBI returned +64.0%, so XBI returned more. One year is one year; the longer windows are in the table.
- Which is cheaper, INDA or XBI?
- INDA charges 0.61% a year and XBI charges 0.35%, so XBI is cheaper. Fees come from each fund's prospectus.
- How much do INDA and XBI overlap with the S&P 500?
- By their latest filed holdings, 0% of INDA and 8% of XBI by weight is stocks the S&P 500 already holds. Between the two funds, 0% of their books are the same securities at the same weight.
Other comparisons
Where to next
Where these figures came from
ETFIQ links to the documents behind every figure. It is not affiliated with any issuer, and a link is not an endorsement.
Cite this page. ETFIQ, INDA against XBI, data as of Sep 12, 2026. https://etfiq.com/compare/any/INDA-XBI Free to use with attribution; the underlying files are at Open data.
A comparison is not a recommendation. Standards and sources